Gary Sherrill, MD
Hematology & Oncology · Greensboro, NCNPI 1003869413
Payments from drug & device makers
Across 13 payments — averaging $12,988 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$169K
- Array Biopharma Inc$60
- GSK$22
- Pharmacosmos Therapeutics Inc.$21
- Foundation Medicine, Inc.$20
- Bristol Myers Squibb$16
- plus $12 from 1 others
What the payments were for
- Food & beverage$13792%
- Education$128%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $168,694 |
| Array Biopharma Inc | 3 | $60 |
| GSK | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$168,843 in reported general payments places this provider in the 75th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $800,050 |
| ImbruvicaIbrutinib | 15 | $237,729 |
| JakafiRuxolitinib Phosphate | 12 | $210,876 |
| CalquenceAcalabrutinib Maleate | 19 | $194,796 |
| Sunitinib Malate | 12 | $93,824 |
| Everolimus | 12 | $93,765 |
| EliquisApixaban | 106 | $79,214 |
| Abiraterone Acetate | 33 | $28,190 |
| Imatinib Mesylate | 11 | $19,730 |
| XareltoRivaroxaban | 14 | $8,704 |
| Hydroxyurea | 45 | $2,126 |
| Prochlorperazine Maleate | 77 | $1,425 |
| Letrozole | 55 | $1,313 |
| Anastrozole | 47 | $899 |
| Potassium Chloride | 71 | $810 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Greensboro
- Vinay GudenaGreensboro$2.5M
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
- Autumn McReeChapel Hill$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.